E-DRUG: Independent Drug and Healthcare Newsletter for April 2021
--------------------------------------------------------------------
Newsletter, April 2021
Independent information by and for healthcare professionals
View the contents
If your friends or colleagues would be interested, forward this email and invite them to sign up for the free Newsletter.
Like what you see?
Subscribe to Prescrire International : Prescrire IN ENGLISH - Offers - Subscribe now, or renew subscription - <span style="font-size:13px">Subscribe or renew online</span>
In Prescrire's Spotlight this month :
FEATURED REVIEW
Larotrectinib (Vitrakvi°) and cancers with an NTRK gene fusion. Grossly inadequate evaluation as of early 2021
Larotrectinib (Vitrakvi°) is the first drug to have been authorised in the European Union for adults and children with a tumour that harbours an NTRK gene fusion. Is this "targeted therapy" on target? What does its authorisation tell us about the evaluation process?
Read more
----------------------------------------------------------------------------
FREE DOWNLOAD
In the April issue of Prescrire International - Hydrochlorothiazide in hypertension: an acceptable first choice
In countries where it is available, chlorthalidone is the first-choice thiazide diuretic. In France, where there is no available medicinal product containing chlorthalidone alone, the first-line thiazide diuretic is hydrochlorothiazide. How do these two drugs compare?
Read more
----------------------------------------------------------------------------
NEWS UPDATE
Covid-19 vaccine Ad26.CoV2S (by Janssen): as with the other covid-19 vaccines, effective in the short term but unknowns remain
Covid-19 vaccine Ad26.CoV2S, marketed by the pharmaceutical company Janssen (part of the Johnson & Johnson group), was authorised in the European Union on 11 March 2021. What are the main data available as of mid-March 2021 from clinical trials of covid-19 vaccine Ad26.CoV2S?
Read more
----------------------------------------------------------------------------
EDITORIAL
40 years: life goes on, so does Prescrire
The women and men who "make" and "are" Prescrire share strong values and work together to support a unique multidisciplinary movement for quality healthcare, launched 40 years ago.
Read more
----------------------------------------------------------------------------
OUTLOOK
Drugs in 2020: a brief review
Just nine of the 109 new drugs, combinations, drug strengths, pharmaceutical forms or indictions analysed and rated in our French edition in 2020 constituted a notable therapeutic advance.
Read more
----------------------------------------------------------------------------
Mediator°: norfenfluramine at the heart of the trial
The verdict in France's Mediator° criminal trial was handed down at the end of March 2021, twelve years after this drug, which caused several hundreds of people to die from pulmonary arterial hypertension (PAH) or heart valve disease, was withdrawn from the French market.
Read more
----------------------------------------------------------------------------
COMING SOON
Enjoy these features, and more, in our upcoming issues <https://communique.prescrire.org/trk/237087/4870/918015316/57526/30128/c24ce4f9/>
Rituximab and pemphigus vulgaris
Ciclosporin eye drops in vernal keratoconjunctivitis
Medical cannabis in chronic pain
Bortezomib as part of first-line treatment for multiple myeloma * Efficacy of antidepressants: overestimated...
Subscribe now
Share this with a friend or colleague: Forward this email!
Prescrire International <international@prescrire.org>